Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards
Obesity
Biotech
ADA: Tolerability questions linger for Boehringer's obesity drug
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
Fraiser Kansteiner
Jun 8, 2026 4:30am
ADA: Roche, Zealand make tolerability case for petrelintide
Jun 7, 2026 3:00am
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
ADA: Pfizer pads case for berobenatide in obesity
Jun 6, 2026 9:29am
Vincentage to chase Lilly to China regulators after obesity win
May 18, 2026 9:23am
Why Lexicon is in ‘good shape to go crazy’: CEO
May 13, 2026 10:50am
